Eurofins expands presence in Discovery Pharmacology with the acquisition of Pan Labs US
Eurofins Scientific, Inc. announced the signing of an agreement to acquire the Pan Labs pharmacology unit that was formerly operated by Ricerca Biosciences LLC and MDS Pharma. Pan Labs is a provider in early stage discovery services with a portfolio that provides molecular pharmacology, functional pharmacology, cellular services, and informatics analytics. The acquisition of this division from Ricerca Biosciences strengthens Eurofins’ growing presence in the US and Taiwan, while adding a unique business possessing the most advanced expertise in high quality Discovery CRO services. Pan Labs has over 150 highly qualified employees and USD 20m in annual revenues with most of the largest global pharmaceutical companies.
Upon closing of the acquisition, which is subject to standard conditions that the parties expect to complete within 30 days, the entity will be renamed Eurofins Pan Laboratories, Inc. and be led by James Baumgartner, Ph.D. who has over 9 years with the Pan Labs organization. Dr. Baumgartner will assume the role as President of Eurofins Pan Laboratories.
Other news from the department business & finance
